SCHEMBL30060976

SCHEMBL30060976

Fc1cc(-c2nc(Cl)c(Cl)c(Cl)n2)ccn1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 1/20 0.45
▸ ADORA2B P29275 6/20 0.43
▸ ADORA2A P29274 3/20 0.43
▸ MAP4K4 O95819 3/20 0.41
▸ MINK1 Q8N4C8 3/20 0.41
▸ TNIK Q9UKE5 3/20 0.41
▸ S1PR1 P21453 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ NQO2 P16083 2/20 0.39
▸ SYK P43405 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ MAPK13 O15264 1/20 0.36
▸ MAPK12 P53778 1/20 0.36
▸ MAPK11 Q15759 1/20 0.36
▸ MAPK14 Q16539 1/20 0.36
▸ LOXL2 Q9Y4K0 1/20 0.36
▸ NFATC1 O95644 1/20 0.36
▸ DYRK1A Q13627 1/20 0.36
▸ MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19995233 1.00 IDO1 (0.45) IDO1ADORA2BADORA2AMAP4K4MINK1
SCHEMBL30062513 0.89 IDO1 (0.45) IDO1ADORA2BADORA2AMAP4K4MINK1
SCHEMBL20012012 0.89 IDO1 (0.45) IDO1ADORA2BADORA2AMAP4K4MINK1
SCHEMBL19995259 0.89 IDO1 (0.40) IDO1ADORA2BADORA2AMAP4K4MINK1
SCHEMBL30062972 0.89 IDO1 (0.40) IDO1ADORA2BADORA2AMAP4K4MINK1
SCHEMBL26030813 0.84 IDO1 (0.53) IDO1ADORA2BADORA2AMAP4K4MINK1
SCHEMBL20012200 0.75 ITGA2B (0.35) IDO1
SCHEMBL22068158 0.75 IDO1 (0.55) IDO1ADORA2BADORA2AMAP4K4MINK1
SCHEMBL30060998 0.75 CLK4 (0.38) LMNADYRK1A
SCHEMBL30298973 0.74 IDO1 (0.52) IDO1ADORA2BADORA2AMAP4K4MINK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110036006-B Preparation and use of pyrimidinone derivatives 癌症研究科技有限公司 2022-12-13 — — CN disclosed
Send feedback